We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

One of the approvals is for Ebglyss, a treatment for atopic dermatitis that could displace the current market leader, ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Both Kisunla and Ebglyss hold the potential to become blockbuster drugs. Investors shouldn't overlook Lilly's pipeline, ...

Accounting for an acquisition Eli Lilly completed in August made a big impact on earnings expectations for 2024.

Eli Lilly & Co. reported its results for the third quarter of 2024, with revenue up 20% y/y but failing to meet market ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...

Over the last 3 months, EPS estimates have seen 0 upward revisions and 13 downward. Revenue estimates have seen 16 upward ...

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger’s ...

The ADapt study assessed the efficacy and safety of EBGLYSS in individuals who had previously been treated with dupilumab.

Lilly scored another big win back in September when the FDA approved its eczema drug, Ebglyss. Although I suspect Lilly will ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY) announced that its drug EBGLYSS, an interleukin-13 (IL-13) inhibitor, has shown to improve skin condition and reduce itchiness in patients with ...